Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul

Executive Summary

The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.

You may also be interested in...



VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High

September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.

Market Intel: Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth

End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.

VC Deals Analysis: Strong In Volume, Soft In Value

June marked a month with the highest deal volume this year to date, although the value of most deals wallowed in the low range. Nonetheless the previous bumper months of March and May meant that the first half of 2017 can boast of having raised the most money, compared to the last four years.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel